Akiyama, Y., Iwanaga, R., Saitoh, K., Shiba, K., Ushio, K., Ikeda, E., Iwama, T., Nomizu, T., Yuasa, Y.. Transforming growth factor beta type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer.. Gastroenterology, (1997);112;33-39.
Arteaga, C., Hurd, S., Winnier, A., Johnson, M., Fendly, B., Forbes, J.. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.. J. Clin. Invest., (1993);92;2569-2576.
Bandyopadhyay, A., Agyin, J. K., Wang, L., Tang, Y., Lei, X., Story, B. M., Cornell, J. E., Pollock, B. H., Mundy, G. R., Sun, L.-Z.. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-β type I receptor kinase inhibitor.. Cancer Res., (2006);66;6714-6721.
Biswas, S., Guix, M., Rinehart, C., Dugger, T. C., Chytil, A., Moses, H. L., Freeman, M. L., Arteaga, C. L.. Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.. J. Clin. Invest., (2007);117;1305-1313.
Bueno, L., de Alwis, D. P., Pitou, C., Yingling, J., Lahn, M., Glatt, S., Troc?niz, I. F.. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice.. Eur. J. Cancer, (2008);44;142-150.
Calone, I., Souchelnytskyi, S.. Inhibition of TGFbeta signaling and its implications in anticancer treatments.. Exp. Oncol., (2012);34;9-16.
Capocasale, R. J., Lamb, R. J., Vonderheid, E. C., Fox, F. E., Rook, A. H., Nowell, P. C., Moore, J. S.. Reduced surface expression of transforming growth factor beta receptor type II in mitogenactivated T cells from Sezary patients.. Proc. Natl. Acad. Sci. U.S.A., (1995);92;5501-5505.
Chen, T., Yan, W., Wells, R. G., Rimm, D. L., McNiff, J., Leffell, D., Reiss, M.. Novel inactivating mutations of transforming growth factor-β type I receptor gene in head-and-neck cancer metastases.. Int. J. Cancer, (2001);93;653-661.
Connolly, E. C., Freimuth, J., Akhurst, R. J.. Complexities of TGF-β targeted cancer therapy.. Int. J. Biol. Sci., (2012);8;964-978.
Connolly, E. C., Saunier, E. F., Quigley, D., Luu, M. T., De Sapio, A., Hann, B., Yingling, J. M., Akhurst, R. J.. Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761.. Cancer Res., (2011);71;2339-2349.
DaCosta Byfield, S. D., Major, C., Laping, N. J., Roberts, A. B.. SB-505124 is a selective inhibitor of transforming growth factor-β type I receptors ALK4, ALK5, and ALK7.. Mol. Pharmacol., (2004);65;744-752.
Datta P. K., Mann J. R.. Transforming growth factor-β (TGF-β) signaling inhibitors cancer therapy in: Transforming Growth Factor-β in Cancer Therapy. In Cancer Treatment and therapy, Volume II: Human Press; (2008). p. 573-587.
Derynck, R., Akhurst, R. J.. Differentiation plasticity regulated by TGF-β family proteins in development and disease.. Nat. Cell Biol., (2007);9;1000-1004.
Derynck, R., Akhurst, R. J., Balmain, A.. TGF-β signaling in tumor suppression and cancer progression.. Nat. Genet., (2001);29;117-129.
Derynck, R., Zhang, Y. E.. Smad-dependent and Smad-independent pathways in TGF-β family signalling.. Nature, (2003);425;577-584.
Dong, M., Blobe, G. C.. Role of transforming growth factor-β in hematologic malignancies.. Blood, (2006);107;4589-4596.
Ehata, S., Hanyu, A., Fujime, M., Katsuno, Y., Fukunaga, E., Goto, K., Ishikawa, Y., Nomura, K., Yokoo, H., Shimizu, T.. Ki26894, a novel transforming growth factor-β type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line.. Cancer Sci., (2007);98;127-133.
Eppert, K., Scherer, S. W., Ozcelik, H., Pirone, R., Hoodless, P., Kim, H., Tsui, L.-C., Bapat, B., Gallinger, S., Andrulis, I. L.. MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma.. Cell, (1996);86;543-552.
Fernandez, T., Amoroso, S., Sharpe, S., Jones, G. M., Bliskovski, V., Kovalchuk, A., Wakefield, L. M., Kim, S.-J., Potter, M., Letterio, J. J.. Disruption of transforming growth factor β signaling by a novel ligand-dependent mechanism.. J. Exp. Med., (2002);195;1247-1255.
Flavell, R. A., Sanjabi, S., Wrzesinski, S. H., Licona-Lim?n, P.. The polarization of immune cells in the tumour environment by TGFβ.. Nat. Rev. Immunol., (2010);10;554-567.
Ganapathy, V., Ge, R., Grazioli, A., Xie, W., Banach-Petrosky, W., Kang, Y., Lonning, S., McPherson, J., Yingling, J. M., Biswas, S.. Targeting the transforming growth factor-β pathway inhibits human basal-like breast cancer metastasis.. Mol. Cancer, (2010);9;122.
Goggins, M., Shekher, M., Turnacioglu, K., Yeo, C. J., Hruban, R. H., Kern, S. E.. Genetic alterations of the transforming growth factor β receptor genes in pancreatic and biliary adenocarcinomas.. Cancer Res., (1998);58;5329-5332.
Gordon, M. S., Ilaria, R. Jr., de Alwis, D. P., Mendelson, D. S., McKane, S., Wagner, M. M., Look, K. Y., LoRusso, P. M.. A Phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors.. Cancer Chemother. Pharmacol., (2013);71;21-27.
Grady, W. M., Myeroff, L. L., Swinler, S. E., Rajput, A., Thiagalingam, S., Lutterbaugh, J. D., Neumann, A., Brattain, M. G., Chang, J., Kim, S.-J.. Mutational inactivation of transforming growth factor β receptor type II in microsatellite stable colon cancers.. Cancer Res., (1999);59;320-324.
Grady, W. M., Rajput, A., Myeroff, L., Liu, D. F., Kwon, K., Willis, J., Markowitz, S.. Mutation of the type II transforming growth factor-β receptor is coincident with the transformation of human colon adenomas to malignant carcinomas.. Cancer Res., (1998);58;3101-3104.
Hagedorn, H. G., Bachmeier, B. E., Nerlich, A. G.. Synthesis and degradation of basement membranes and extracellular matrix and their regulation by TGF-β in invasive carcinomas (Review).. Int. J. Oncol., (2001);18;669-681.
Hau, P., Jachimczak, P., Schlingensiepen, R., Schulmeyer, F., Jauch, T., Steinbrecher, A., Brawanski, A., Proescholdt, M., Schlaier, J., Buchroithner, J.. Inhibition of TGF-β 2 with ap 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies.. Oligonucleotides, (2007);17;201-212.
Heldin, C.-H., Miyazono, K., Ten Dijke, P.. TGF-β signalling from cell membrane to nucleus through SMAD proteins.. Nature, (1997);390;465-471.
Hjelmeland, M. D., Hjelmeland, A. B., Sathornsumetee, S., Reese, E. D., Herbstreith, M. H., Laping, N. J., Friedman, H. S., Bigner, D. D., Wang, X.-F., Rich, J. N.. SB-431542, a small molecule transforming growth factor-β-receptor antagonist, inhibits human glioma cell line proliferation and motility.. Mol. Cancer Ther., (2004);3;737-745.
Kang, Y., He, W., Tulley, S., Gupta, G. P., Serganova, I., Chen, C.-R., Manova-Todorova, K., Blasberg, R., Gerald, W. L., Massagu?, J.. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway.. Proc. Natl. Acad. Sci. U.S.A., (2005);102;13909-13914.
Kang, Y., Siegel, P. M., Shu, W., Drobnjak, M., Kakonen, S. M., Cord?n- Cardo, C., Guise, T. A., Massagu?, J.. A multigenic program mediating breast cancer metastasis to bone.. Cancer Cell, (2003);3;537-549.
Kingsley, D. M.. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms.. Genes Dev., (1994);8;133-146.
Kingsley, L. A., Fournier, P. G., Chirgwin, J. M., Guise, T. A.. Molecular biology of bone metastasis.. Mol. Cancer Ther., (2007);6;2609-2617.
Korpal, M., Yan, J., Lu, X., Xu, S., Lerit, D. A., Kang, Y.. Imaging transforming growth factor-β signaling dynamics and therapeutic response in breast cancer bone metastasis.. Nat. Med., (2009);15;960-966.
Lampropoulos, P., Zizi-Sermpetzoglou, A., Rizos, S., Kostakis, A., Nikiteas, N., Papavassiliou, A. G.. TGF-beta signalling in colon carcinogenesis.. Cancer Lett., (2012);314;1-7.
Lee, G. Y., Kenny, P. A., Lee, E. H., Bissell, M. J.. Three-dimensional culture models of normal and malignant breast epithelial cells.. Nat. Methods, (2007);4;359-365.
Levy, L., Hill, C. S.. Alterations in components of the TGF-β superfamily signaling pathways in human cancer.. Cytokine Growth Factor Rev., (2006);17;41-58.
Lindley, L. E., Briegel, K. J.. Molecular characterization of TGFβ-induced epithelial-mesenchymal transition in normal finite lifespan human mammary epithelial cells.. Biochem. Biophys. Res. Commun., (2010);399;659-664.
Maliekal, T. T., Antony, M.-L., Nair, A., Paulmurugan, R., Karunagaran, D.. Loss of expression, and mutations of Smad 2 and Smad 4 in human cervical cancer.. Oncogene, (2003);22;4889-4897.
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M.. The epithelial-mesenchymal transition generates cells with properties of stem cells.. Cell, (2008);133;704-715.
Markowitz, S., Wang, J., Myeroff, L., Parsons, R., Sun, L., Lutterbaugh, J., Fan, R. S., Zborowska, E., Kinzler, K. W., Vogelstein, B.. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability.. Science, (1995);268;1336-1338.
Massagu?, J.. How cells read TGF-β signals.. Nat. Rev. Mol. Cell Biol., (2000);1;169-178.
Massagu?, J.. TGFβ in cancer.. Cell, (2008);134;215-230.
Massagu?, J., Gomis, R. R.. The logic of TGFβ signaling.. FEBS Lett., (2006);580;2811-2820.
Matsuyama, S., Iwadate, M., Kondo, M., Saitoh, M., Hanyu, A., Shimizu, K., Aburatani, H., Mishima, H. K., Imamura, T., Miyazono, K.. SB-431542 and Gleevec inhibit transforming growth factor-β-induced proliferation of human osteosarcoma cells.. Cancer Res., (2003);63;7791-7798.
Melisi, D., Ishiyama, S., Sclabas, G. M., Fleming, J. B., Xia, Q., Tortora, G., Abbruzzese, J. L., Chiao, P. J.. LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.. Mol. Cancer Ther., (2008);7;829-840.
Meulmeester, E., ten Dijke, P.. The dynamic roles of TGF-β in cancer.. J. Pathol., (2011);223;205-218.
Micalizzi, D. S., Christensen, K. L., Jedlicka, P., Coletta, R. D., Bar?n, A. E., Harrell, J. C., Horwitz, K. B., Billheimer, D., Heichman, K. A., Welm, A. L.. The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-β signaling.. J. Clin.Invest., (2009);119;2678-2690.
Micalizzi, D. S., Wang, C.-A., Farabaugh, S. M., Schiemann, W. P., Ford, H. L.. Homeoprotein Six1 increases TGF-β Type I receptor and converts TGF-β signaling from suppressive to supportive for tumor growth.. Cancer Res., (2010);70;10371-10380.
Mishra, L., Derynck, R., Mishra, B.. Transforming growth factor-β signaling in stem cells and cancer.. Science, (2005);310;68-71.
Mohammad, K. S., Javelaud, D., Fournier, P. G., Niewolna, M., McKenna, C. R., Peng, X. H., Duong, V., Dunn, L. K., Mauviel, A., Guise, T. A.. TGF-β-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases.. Cancer Res., (2011);71;175-184.
Moon, J., Kim, H., Cho, I., Sheen, Y., Kim, D.. IN-1130, a novel transforming growth factor-β type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy.. Kidney Int., (2006);70;1234-1243.
Muraoka-Cook, R. S., Dumont, N., Arteaga, C. L.. Dual role of transforming growth factor β in mammary tumorigenesis and metastatic progression.. Clin. Cancer Res., (2005);11;937s-943s.
Muraoka, R. S., Dumont, N., Ritter, C. A., Dugger, T. C., Brantley, D. M., Chen, J., Easterly, E., Roebuck, L. R., Ryan, S., Gotwals, P. J.. Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases.. J. Clin. Invest., (2002);109;1551-1559.
Nam, J.-S., Terabe, M., Mamura, M., Kang, M.-J., Chae, H., Stuelten, C., Kohn, E., Tang, B., Sabzevari, H., Anver, M. R.. An anti-transforming growth factor β antibody suppresses metastasis via cooperative effects on multiple cell compartments.. Cancer Res., (2008);68;3835-3843.
Padua, D., Massagu?, J.. Roles of TGFβ in metastasis.. Cell Res., (2009);19;89-102.
Padua, D., Zhang, X. H.-F., Wang, Q., Nadal, C., Gerald, W. L., Gomis, R. R., Massague, J.. TGFβ primes breast tumors for lung metastasis seeding through angiopoietin-like 4.. Cell, (2008);133;66-77.
Park, C.-Y., Son, J.-Y., Jin, C. H., Nam, J.-S., Kim, D.-K., Sheen, Y. Y.. EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung.. Eur. J. Cancer, (2011a);47;2642-2653.
Park, C. Y., Kim, D. K., Sheen, Y. Y.. EW-7203, a novel small molecule inhibitor of transforming growth factor-β (TGF-β) type I receptor/activin receptor/like kinase-5, blocks TGF-β1- mediated epithelial-to-mesenchymal transition in mammary epithelial cells.. Cancer Sci., (2011b);102;1889-1896.
Parsons, R., Myeroff, L. L., Liu, B., Willson, J. K., Markowitz, S. D., Kinzler, K. W., Vogelstein, B.. Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer.. Cancer Res., (1995);55;5548-5550.
Peng, H., Carretero, O. A., Vuljaj, N., Liao, T.-D., Motivala, A., Peterson, E. L., Rhaleb, N.-E.. Angiotensin-converting enzyme inhibitors a new mechanism of action.. Circulation, (2005);112;2436-2445.
Porter, P. L.. Global trends in breast cancer incidence and mortality.. Salud Publica Mex., (2009);51;s141-s146.
Roberts, A. B., Wakefield, L. M.. The two faces of transforming growth factor β in carcinogenesis.. Proc. Natl. Acad. Sci. U.S.A., (2003);100;8621-8623.
Rowland-Goldsmith, M. A., Maruyama, H., Matsuda, K., Idezawa, T., Ralli, M., Ralli, S., Korc, M.. Soluble type II transforming growth factor-β receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis1.. Mol. Cancer Ther., (2002);1;161-167.
S?nchez-Elsner, T., Botella, L. M., Velasco, B., Corb?, A., Attisano, L., Bernab?u, C.. Synergistic cooperation between hypoxia and transforming growth factor-β pathways on human vascular endothelial growth factor gene expression.. J. Biol. Chem., (2001);276;38527-38535.
S?nchez-Zamorano, L. M., Flores-Luna, L., S?nchez-Zamorano, A., Romieu, I., Lazcano-Ponce, E., Miranda-Hern?ndez, H., Mainero- Ratchelous, F., Torres-Mej?a, G.. Healthy lifestyle on the risk of breast cancer.. Cancer Epidemiol. Biomarkers Prev., (2011);20;912-922.
Sawyer, T. K.. Novel oncogenic protein kinase inhibitors for cancer therapy.. Curr. Med. Chem. Anticancer Agents, (2004);4;449-455.
Schlingensiepen, K. H., Jaschinski, F., Lang, S. A., Moser, C., Geissler, E. K., Schlitt, H. J., Kielmanowicz, M., Schneider, A.. Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer.. Cancer Sci., (2011);102;1193-1200.
Shi, Y., Massagu?, J.. Mechanisms of TGF-β signaling from cell membrane to the nucleus.. Cell, (2003);113;685-700.
Shinto, O., Yashiro, M., Kawajiri, H., Shimizu, K., Shimizu, T., Miwa, A., Hirakawa, K.. Inhibitory effect of a TGFβ receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells.. Br. J. Cancer, (2010);102;844-851.
Shirakihara, T., Horiguchi, K., Miyazawa, K., Ehata, S., Shibata, T., Morita, I., Miyazono, K., Saitoh, M.. TGF-β regulates isoform switching of FGF receptors and epithelial-mesenchymal transition.. EMBO J., (2011);30;783-795.
Subramanian, G., Schwarz, R. E., Higgins, L., McEnroe, G., Chakravarty, S., Dugar, S., Reiss, M.. Targeting endogenous transforming growth factor β receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype 1.. Cancer Res., (2004);64;5200-5211.
Takenoshita, S., Tani, M., Nagashima, M., Hagiwara, K., Bennett, W. P., Yokota, J., Harris, C. C.. Mutation analysis of coding sequences of the entire transforming growth factor beta type II receptor gene in sporadic human colon cancer using genomic DNA and intron primers.. Oncogene, (1997);14;1255-1258.
Takeuchi, K., Abe, M., Hiasa, M., Oda, A., Amou, H., Kido, S., Harada, T., Tanaka, O., Miki, H., Nakamura, S.. TGF-β inhibition restores terminal osteoblast differentiation to suppress myeloma growth.. PLoS One, (2010);5;e9870.
Tanaka, H., Shinto, O., Yashiro, M., Yamazoe, S., Iwauchi, T., Muguruma, K., Kubo, N., Ohira, M., Hirakawa, K.. Transforming growth factor β signaling inhibitor, SB-431542, induces maturation of dendritic cells and enhances anti-tumor activity.. Oncol. Rep., (2010);24;1637-1643.
Thiery, J. P., Acloque, H., Huang, R. Y., Nieto, M. A.. Epithelial- mesenchymal transitions in development and disease.. Cell, (2009);139;871-890.
Thomas, D. A., Massagu?, J.. TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance.. Cancer Cell, (2005);8;369-380.
Thuault, S., Valcourt, U., Petersen, M., Manfioletti, G., Heldin, C.-H., Moustakas, A.. Transforming growth factor-β employs HMGA2 to elicit epithelial-mesenchymal transition.. J. Cell Biol., (2006);174;175-183.
Travis, R. C., Reeves, G. K., Green, J., Bull, D., Tipper, S. J., Baker, K., Beral, V., Peto, R., Bell, J., Zelenika, D.. Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study.. Lancet, (2010);375;2143-2151.
Uhl, M., Aulwurm, S., Wischhusen, J., Weiler, M., Ma, J. Y., Almirez, R., Mangadu, R., Liu, Y.-W., Platten, M., Herrlinger, U.. SD- 208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.. Cancer Res., (2004);64;7954-7961.
van Meeteren, L. A., Thorikay, M., Bergqvist, S., Pardali, E., Stampino, C. G., Hu-Lowe, D., Goumans, M.-J., ten Dijke, P.. Antihuman activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting.. J. Biol. Chem., (2012);287;18551-18561.
Viloria-Petit, A. M., David, L., Jia, J. Y., Erdemir, T., Bane, A. L., Pinnaduwage, D., Roncari, L., Narimatsu, M., Bose, R., Moffat, J.. A role for the TGFβ-Par6 polarity pathway in breast cancer progression.. Proc. Natl. Acad. Sci. U.S.A., (2009);106;14028-14033.
Wakefield, L. M., Roberts, A. B.. TGF-β signaling: positive and negative effects on tumorigenesis.. Curr. Opin. Genet. Dev., (2002);12;22-29.
Wang, D., Kanuma, T., Mizunuma, H., Takama, F., Ibuki, Y., Wake, N., Mogi, A., Shitara, Y., Takenoshita, S.. Analysis of specific gene mutations in the transforming growth factor-β signal transduction pathway in human ovarian cancer.. Cancer Res., (2000);60;4507-4512.
Wendt, M. K., Smith, J. A., Schiemann, W. P.. Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression.. Oncogene, (2010);29;6485-6498.
Wiercinska, E., Naber, H. P., Pardali, E., van der Pluijm, G., van Dam, H., ten Dijke, P.. The TGF-β/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system.. Breast Cancer Res. Treat., (2011);128;657-666.
Yakicier, M., Irmak, M., Romano, A., Kew, M., Ozturk, M.. Smad2 and Smad4 gene mutations in hepatocellular carcinoma.. Oncogene, (1999);18;4879-4883.
Yang, Y.-A., Dukhanina, O., Tang, B., Mamura, M., Letterio, J. J., Mac- Gregor, J., Patel, S. C., Khozin, S., Liu, Z.-y., Green, J.. Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects.. J. Clin. Invest., (2002);109;1607-1615.
Yingling, J. M., Blanchard, K. L., Sawyer, J. S.. Development of TGF-β signalling inhibitors for cancer therapy.. Nat. Rev. Drug Discov., (2004);3;1011-1022.
Zhang, B., Halder, S. K., Zhang, S., Datta, P. K.. Targeting transforming growth factor-β signaling in liver metastasis of colon cancer.. Cancer Lett., (2009);277;114-120.
Zhang, Y., Derynck, R.. Regulation of Smad signalling by protein associations and signalling crosstalk.. Trends Cell Biol., (1999);9;274-279.